Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      Phase Ib Study of SC Milatuzumab in SLE
      Description

      Milatuzumab will be given subcutaneously at different dose levels once (depending on the dose level) for 4 weeks to determine if milatuzumab helps to control lupus (SLE).

      Conditions
      Lupus Erythematosus, CutaneousLupus Erythematosus, DiscoidLupus Erythematosus, SystemicLupus Vasculitis, Central Nervous SystemLupus Nephritis
      Talk to us
      TERMINATED
      GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases
      Description

      The purpose of this study it to determine whether the use of a gonadotropin releasing hormone (GnRH)-agonist (depot-leuprolide acetate) during cyclophosphamide (CYC) therapy in women with rheumatic diseases will provide greater ovarian protection than placebo.

      Conditions
      Lupus Erythematosus, SystemicSystemic VasculitisIsolated Angiitis of Central Nervous SystemLung Disease With Systemic SclerosisLung Disease Interstitial Diffuse
      Talk to us